Alcon

Elaine E. Whitbeck is senior vice president, chief legal officer, general counsel and corporate secretary for Alcon, the world’s largest eye care company. Ms. Whitbeck joined Alcon in 1986 and is responsible for all Alcon legal matters, including those pertaining to securities, intellectual property and patents, acquisition and divestiture transactions, employment issues, litigation, transactional matters, environmental law, real estate/construction, computer/internet issues, regulatory concerns (FDA, FTC, PDMA, OSHA), antitrust issues, benefits, banking/treasury, contract administration and records management. Ms. Whitbeck was also elected to the Supervisory Board of WaveLight AG in March 2008. Prior to joining Alcon, Ms. Whitbeck was the director of legal operations and shareholder services for Mary Kay Cosmetics, Inc., where she handled product liability claims/litigation, antitrust issues and securities-related matters. Previously, she was a trial attorney with the Dallas law firm of Vial, Hamilton, Koch & Knox. Ms. Whitbeck also served as protocol assistant to Secretaries of Defense James Schlesinger and Donald Rumsfeld in Washington, D.C. Ms. Whitbeck received a Bachelor of Arts, Summa Cum Laude, Phi Beta Kappa, and Echols Scholar, and a Juris Doctor degree from the University of Virginia. She completed the Harvard Business School’s Program for Management and Development in 1993. Ms. Whitbeck served as the statewide president for the Texas General Counsel Forum in 2002 and 2003 and continues to serve on the statewide board. She also serves on the Advisory Board for the SMU Corporate Counsel Symposium, was a 2004 Honoree for the YWCA’s Tribute to Women in Business and was honored with a Women of Influence Award for the "2005 Great Women of Texas Event" by the Fort Worth Business Press. Ms. Whitbeck is a board member of Prevent Blindness America – Texas Chapter, the Lena Pope Home (child protection and adoption) and ORBIS International (the "Flying Eye Hospital").

Jacqualyn Fouse was named senior vice president and chief financial officer of Alcon, the world's largest eye care company, in July 2002. Her global responsibilities include management of all financial functions for the company as well as Information Technology, Investor Relations, Strategic Corporate Communications, Humanitarian/ Community Services and coordination of the development and execution of corporate strategy. Ms. Fouse joined Alcon in 1986 and has served in a variety of financial positions throughout the company. In 1993, she moved to Switzerland to join parent company Nestle as assistant controller for the Pharma-Cosmetics group, responsible for coordinating all of Alcon's financial and operating relationships with Nestle. After spending three years in this position, Ms. Fouse was promoted to deputy treasurer and later to group treasurer of Nestle. She left Nestle to become chief financial officer of the Swissair Group in June 2001. Ms. Fouse holds Bachelor of Arts and Master of Arts degrees in Economics from the University of Texas at Arlington and has recently attained "all but dissertation" status for her Ph.D. in Finance and Administration. Ms. Fouse has received numerous awards and honors including the 2005 Financial Executive of the Year Award from the Institute of Management Accountants and Robert Half International, the University of Texas at Arlington Distinguished Alumni Award, and selection as a "Great Woman of Texas" by the Fort Worth Business Press. Ms. Fouse is actively involved in her community and various educational and philanthropic endeavors, locally and around the world. She was selected as a World Economic Forum Global Leader for Tomorrow and serves on the Board of Directors of ORBIS International, a non-profit organization dedicated to saving sight and eliminating preventable blindness, the Corporate Working Group of the Board of the International Association for the Prevention of Blindness, the Board and Advisory Council of Ophthalmic Women Leaders and several boards and advisory councils for universities in the Dallas-Fort Worth area.

Mr. Singh joined the Alcon, Inc. board in July 2008 following the closing of the sale of the 24.85 percent minority interest of Alcon, Inc. by Nestle S.A. to Novartis AG. In 2008, Mr. Singh was appointed Executive Vice President and Chief Financial Officer of Nestle S.A. He began his career in 1977 as a financial analyst for Nestle Canada. From 1980 to 1995 he held various positions relating to finance and treasury in Nestle Canada. Between 1995 and 2000 he was Executive Vice President and Chief Financial Officer of Nestle Canada. Between 2000 and 2008 he was Senior Vice President, Acquisitions and Business Development of Nestle S.A. during which period he was, amongst others, involved in Alcon's IPO in 2002. Mr. Singh graduated as Bachelor of Social Science from the University of Guyana and obtained his Master of Business Administration at the University of Windsor in Canada. In 1980, Mr. Singh graduated as Certified Management Accountant.

Sabri Markabi, M.D., is the senior vice president of Research and Development and Chief Medical Officer of Alcon Laboratories, Inc., a subsidiary of Alcon, Inc., the world’s largest eye care company. He manages and directs Alcon’s global Research and Development efforts and Regulatory Affairs department. Dr. Markabi was chosen to take over the role of senior vice president research and development and Chief Scientific Officer in March 2008. Dr. Markabi began his career as a staff neurologist on the faculty of the University Hospital in Tours, France. In 1991, he joined CIBA-GEIGY and assumed positions of increasing responsibilities in France, Switzerland, and New Jersey. In 2004 Novartis appointed him vice president, global head of Development for the Ophthalmic Business Unit, were he oversaw the Development organization including R&D strategy, experimental medicine, clinical development and regulatory affairs. Dr. Markabi received his medical degree in 1982 from the University of Damascus in Syria. He completed his clinical training and obtained the French Certification in neurology, with additional qualifications in neuropsycopharmacology from the University of Pierre et Marie Curie, Paris, France.

Andre Bens, Ph.D. was named Senior Vice President, Global Manufacturing and Technical Support of Alcon Laboratories, Inc. in January 2001. His current responsibilities include Alcon's Manufacturing, Quality Assurance, Engineering, Corporate Purchasing, U.S. Distribution and Customer Service - covering most of the supply chain management. Andre joined Alcon in 1982 as Quality Assurance Manager and Responsible Pharmacist at the Puurs manufacturing operation in Belgium. After transferring to Fort Worth, Texas in 1985, he progressed through various positions in Quality Assurance and Manufacturing, culminating in his assignment as Vice President Manufacturing and Engineering in 1993. In 1999, management of the Quality Assurance and Corporate Purchasing and U.S. Distribution were added to his responsibilities. Andre studied at the Universities of Antwerp and Ghent in Belgium and holds Pharmacy and Ph.D. degrees from the University of Ghent. He is a Certified Industrial Pharmacist. Andre is also a graduate of the 1990 Harvard International Senior Management Program.

Hermann Wirz. Mr. Wirz is proposed to be elected to the board of directors as a replacement for Paul Polman who resigned from Alcon's board of directors effective September 6, 2008. Mr. Polman was a member of the class of directors whose term of office would expire in 2011. Mr. Wirz is proposed to be elected to the board of directors for a two-year term of office. Mr. Wirz began his career in 1968 in financial and management accounting for Electrical Company Lucerne Switzerland. From 1969 through 1971, he held a management accounting position for Shell Switzerland. He joined Nestle in 1972 and worked in industrial accounting and budgeting functions for Nestle England, Spain and Venezuela. He subsequently was appointed Manager Operational Control Latin America for Nestec Switzerland in 1980 and in 1984 was promoted to Director of Finance & Control for Nestle Peru, and for Nestle Venezuela in 1989. Mr. Wirz was appointed Executive Vice President and Chief Financial Officer of Nestle Mexico in 1995 and served in that position through 2000. In 2001, he was appointed Chief Accounting Officer (Senior Vice President as Head of Group Accounting and Reporting) for Nestle S.A., Switzerland. He was a member of the Swiss Chamber of Commerce in Peru, Venezuela and Mexico and also a member of the Admission Board of the Swiss Stock Exchange. He achieved his degree in Business Administration from Lucerne, Switzerland, and has completed the Programme for Executive Development at the International Institute for Management Development (IMD) in Lausanne, Switzerland. Under the terms of the Shareholders Agreement (as defined in Item 7.B. "Related Party Transactions") that Nestle entered into with Novartis in connection with Nestle's sale of 74,061,237 Alcon, Inc. common shares to Novartis, the parties agreed to use their reasonable best efforts to cause the number of our board of directors to be ten; subject to election and the due qualification of such individuals as directors, our board of directors shall be comprised of (A) one individual designated by Novartis, (B) five individuals designated by Nestle, (C) three individuals nominated by the Nominating/Corporate Governance Committee that qualify as independent directors and who are not Novartis or Nestle designees and (D) the Chief Executive Officer of Alcon, Inc. If a Nestle-nominated director resigns from office, Nestle will have the right to nominate a replacement director. If a Novartis-nominated director resigns from office, Novartis will have the right to nominate a replacement director. Any vacancies among our independent directors will be filled by another independent person who will be nominated by the full board of directors.

Francisco Castaner. Mr. Castaner joined the Alcon, Inc. board in July 2001. He has served as Executive Vice President, Pharmaceutical and Cosmetic Products, Liaison with L'Oreal S.A., Human Resources and Corporate Affairs of Nestle since 1997. In 1987, Mr. Castaner was named Managing Director and in 1991 Vice President of the Board of Nestle Espana S.A., holding this position until his transfer to Switzerland and his promotion to Executive Vice President of Nestle in June 1997. Prior to 1987, Mr. Castaner was employed by Nestle in various capacities both in Switzerland and in Spain. Mr. Castaner began his career with Nestle in the Market Research Department of Nestle Espana S.A. in 1964. Mr. Castaner serves as a director of Galderma Pharma S.A., L'Oreal S.A. and Uprona (Canada) Ltd.

Bert Davis founded Chase Medical in 1995 and currently serves as Chairman and CEO. He has over 17 years of healthcare industry and medical device experience in sales, marketing, and operations for The Cooper Companies, Alcon Inc., Shiley Inc., Pfizer Inc., and Quest Medical Inc. Mr.Davis also served in various leadership positions as an infantry officer in the United States Army. Mr.Davis holds a Bachelor of Science degree from the U.S. Military Academy, at West Point.

Bill Barton is senior vice president, International Markets of Alcon Laboratories, Inc., a subsidiary of Alcon, Inc., the world’s largest eye care company. In this role, Mr. Barton is responsible for the management of International Markets and the Global Marketing Committee. Mr. Barton joined Alcon in 1989 (following the acquisition of CooperVision) as group product director, marketing, Surgical Products. Since that time, he has held positions of increasing responsibility in all divisions including vice president of marketing for Surgical from 1991 – 1995, vice president of marketing in Pharmaceutical from 1996 – 1998, and vice president of sales for Primary Care from 1999 – 2000. In 2001 he returned to the Surgical Division as vice president and general manager. He gained international experience from 2004 – 2007 as vice president/area president of Canada, Australia and Far East. Most recently he served as vice president/area president of U.S. and Global Marketing, a position he has held since 2007. Mr. Barton began his career in ophthalmology with Allergan Pharmaceuticals in 1978, as a sales representative. In 1982, he joined Syntex Ophthalmics where he various positions in sales and marketing. He joined CooperVision in 1985 which was later acquired by Alcon. He holds a Bachelor of Science in Business Administration from Southern Utah State University, as well as a Masters of Business Administration from the University of Utah. He is also a graduate of the Harvard Executive Program.

Ed McGough is senior vice president, Global Manufacturing and Technical Operations of Alcon Laboratories, Inc., a subsidiary of Alcon, Inc., the world’s largest eye care company. In this role, Mr. McGough is responsible for the company’s Manufacturing, Quality Assurance, Engineering, Global Supply Chain, U.S. Distribution, Corporate Purchasing, Safety and Environmental Affairs and Customer Service. Mr. McGough joined Alcon in April 1991 as a manager of quality assurance and regulatory affairs in the company’s Sinking Spring, Pennsylvania facility. Following this role, Mr. McGough held various positions at Alcon in both Fort Worth, Texas and Puerto Rico, including director of quality assurance, director of operations and director of manufacturing. He has also served as vice president and general manager of Fort Worth and Houston manufacturing. Most recently, Mr. McGough served as vice president, Manufacturing, Pharmaceutical Operations, responsible for the company’s pharmaceutical plants in United States, Brazil, Mexico, Spain, Belgium and France. Prior to joining Alcon, Mr. McGough served in various quality engineering/management roles with Baxter Healthcare Corporation. He is also a member of the International Society for Pharmaceutical Engineering and the Parenteral Drug Association. Mr. McGough earned a Bachelor of Science in Industrial Engineering from Louisiana Tech University in 1983. He is also a 1999 graduate of the Stanford Executive Program.

With over 10 years of business development and marketing experience within the financial planning and health care business community, he has a well defined ability to listen and develop a strong understanding of what prospects and clients need. Since 1994 he has provided impeccable service to doctors and health care related business owners while working with such financial and pharmaceutical firms as Axa, Alcon, and Dentsply. During his tenure with these firms he managed a variety of sales territories and developed markets exceeding $50M in revenue. He is a multiple time recipient of high standard achievement awards, including various "Presidential" sales awards for exceeding client expectations. As Senior-Vice President of Sales/Marketing and Co-Founder of Healthcare Business Brokers, Inc., he oversaw all business development strategies. Now with the merger to HCBB Properties, Mauricio remains as the company's Senior Vice-President and heads the Health Services Marketing Division, which is responsible for planning, implementing and managing the marketing campaigns for all of the company's affiliate medical services partners.

Dr. Vasella joined the Alcon, Inc. board in July 2008 following the closing of the sale of the 24.85 percent minority interest of Alcon, Inc. by Nestlé S.A. to Novartis AG. Since 1996 Dr. Vasella has served as Chief Executive Officer of the Novartis Group and as executive member of the Board of Directors of Novartis AG. In 1999, he additionally was appointed Chairman of the Board of Directors of Novartis AG. Dr. Vasella graduated with an M.D. from the University of Berne in 1979. After holding a number of medical positions in Switzerland, he joined Sandoz Pharmaceuticals Corporation in the U.S.A. in 1988. From 1993 to 1995, Dr. Vasella advanced from Head of Corporate Marketing to Senior Vice President and Head of Worldwide Development to Chief Operating Officer of Sandoz Pharma Ltd. In 1995 and 1996, Dr. Vasella was a member of the Sandoz Group Executive Committee and Chief Executive Officer of Sandoz Pharma Ltd. Dr. Vasella is a member of the Board of Directors of Pepsico, Inc., United States, a member of the Board of Dean’s Advisors at the Harvard Business School, and a member of the INSEAD Board of Directors.

Gerhard N. Mayr, Independent Director, Member of the Remuneration and Appointments Committee. A native of Austria, Gerhard Mayr received a master's degree in chemical engineering from the Swiss Federal Institute of Technology (Zurich, Switzerland) in 1969, and a master of business administration degree from Stanford University in 1972. In March, 2004, Gerhard Mayr retired as executive vice president of pharmaceutical operations at Eli Lilly & Company after 32 years of service. He had been responsible for global pharmaceutical operations and sales and marketing worldwide at Lilly - a leading innovation-driven corporation. Gerhard Mayr is past chairman of both the International Executive Committee and the Europe Committee of the Pharmaceutical Research Manufacturers of America. He was a board member of the European Federation of the Pharmaceutical Industry from 1995-97 and 2000-2002. Member of the Board of Bank Austria-Creditanstalt AG, and a member of the board of OMV AG. He is a member of the Apax Healthcare Advisory Board, a member of the board of Project Hope, and a board member of the Vienna Science-Research and Technology Foundation.

Joan W. Miller, M.D. is chief and chair of ophthalmology and Henry Willard Williams professor of ophthalmology at the Massachusetts Eye and Ear Infirmary and Harvard Medical School. Dr. Miller's research interests are focused on ocular neovascularization, particularly as it relates to macular degeneration and diabetic retinopathy, including the role of growth factors, the development of antiangiogenic therapy and photodynamic therapy. Dr. Miller has received numerous awards, including the Rosenthal Award of the Macula Society, the Retina Research Award from the Club Jules Gonin and the Alcon Research Institute Award. Dr. Miller's professional affiliations include the American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, Inc. (ARVO) and the New England Ophthalmological Society (NEOS). Dr. Miller earned her Bachelor of Science degree from the Massachusetts Institute of Technology and her medical degree from Harvard Medical School

Mr. de Vink joined the Alcon, Inc. board in March 2002. Mr. de Vink has served as Founding Partner of Blackstone Health Care Partners since April 2003. Prior to that, he was Chairman, International Health Care Partners from November 2000. Mr. de Vink was formerly Chairman, President and CEO of Warner-Lambert Company. Mr. de Vink is a member of the board of directors of Roche Holding AG and Flamel Technologies S.A. Mr. de Vink is also a member of Sotheby's International Advisory Board and a member of the European Advisory Council of Rothschild & Cie.

Paul Bulcke joined the Alcon, Inc. board in May 2008. He is a member of the Board of Directors of Nestlé S.A. and serves as Nestlé's chief executive officer. He was elected to Nestlé's board and appointed to his position on April 10, 2008. Mr. Bulcke has had a long and distinguished career within the Nestle group since 1979, where he advanced through the sales and marketing divisions and then into regional executive management. Most recently, Mr. Bulcke was Executive Vice President and Director for Zone Americas in addition to serving as Co-Chairman of Beverage Partners Worldwide S.A. and Co-Chairman of the Supervisory Board of Cereal Partners Worldwide. Mr. Bulcke graduated from the University of Leuven as a Commercial Engineer and obtained his post graduate in Management at the University of Gent in Belgium.

Chairman, Fox Run Capital Associates, Irving, Texas

Dr. Bauer joined the Alcon, Inc. board in March 2002 and has served as Executive Vice President, Technical, Production, Environment and R&D of Nestlé since May 2002. In February 2007, he was appointed Chief Technology Officer, Head of Innovation, Technology R&D. Dr. Bauer began his career with Nestlé in 1990 as Head of Nestlé Research Center in Lausanne, Switzerland. In 1996, he became Head of R&D worldwide. In 1998, he moved to South Africa as Technical Manager for Nestlé South and East Africa and in 2000 he took over the position of Managing Director, Nestlé South and East Africa. Dr. Bauer is Chairman and a director of Sofinol S.A. and Vice Chairman and a director of Life Ventures S.A. and Nutrition-Wellness Venture AG. Dr. Bauer also serves as a director of L'Oréal S.A. and Uprona (Canada) Ltd. He is a member of the Supervisory Board of Cereal Partners Worldwide (CPW) and Chairman of the Supervisory Board of Nestlé Deutschland AG. Dr. Bauer is a member of the Board of Trustees of the Bertelsmann Foundation, Germany, and a board member of the Swiss Society of Chemical Industries, Switzerland.